These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32773463)

  • 21. The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease.
    Lattanzi B; Nardelli S; Pigliacelli A; Di Cola S; Farcomeni A; D'Ambrosio D; Gioia S; Ginanni Corradini S; Lucidi C; Mennini G; Rossi M; Merli M; Riggio O
    Dig Liver Dis; 2019 Nov; 51(11):1508-1512. PubMed ID: 31601536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
    Teng D; Zuo H; Liu L; Dong J; Ding L
    Virol J; 2018 Oct; 15(1):151. PubMed ID: 30285813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites.
    Kim JJ; Kim JH; Koo JK; Choi YJ; Ko SY; Choe WH; Kwon SY
    Clin Mol Hepatol; 2014 Mar; 20(1):47-55. PubMed ID: 24757658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and spontaneous bacterial peritonitis.
    Chen PC; Chen BH; Huang CH; Jeng WJ; Hsieh YC; Teng W; Chen YC; Ho YP; Sheen IS; Lin CY
    Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1256-1263. PubMed ID: 31498284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bedside Measures of Frailty and Cognitive Function Correlate with Sarcopenia in Patients with Cirrhosis.
    Tapper EB; Derstine B; Baki J; Su GL
    Dig Dis Sci; 2019 Dec; 64(12):3652-3659. PubMed ID: 31292783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical, neuropsychological and neurophysiological indices and predictors of hepatic encephalopathy (HE).
    Formentin C; Zarantonello L; Mangini C; Frigo AC; Montagnese S; Merkel C
    Liver Int; 2021 May; 41(5):1070-1082. PubMed ID: 33411388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
    Varakanahalli S; Sharma BC; Srivastava S; Sachdeva S; Dahale AS
    Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
    J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis.
    Pantham G; Post A; Venkat D; Einstadter D; Mullen KD
    Dig Dis Sci; 2017 Aug; 62(8):2166-2173. PubMed ID: 28560484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.
    Lunia MK; Sharma BC; Sharma P; Sachdeva S; Srivastava S
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1003-8.e1. PubMed ID: 24246768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a novel frailty index to predict mortality in patients with end-stage liver disease.
    Lai JC; Covinsky KE; Dodge JL; Boscardin WJ; Segev DL; Roberts JP; Feng S
    Hepatology; 2017 Aug; 66(2):564-574. PubMed ID: 28422306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis.
    Labenz C; Nagel M; Kremer WM; Hilscher M; Schilling CA; Toenges G; Kuchen R; Schattenberg JM; Galle PR; Wörns MA
    Aliment Pharmacol Ther; 2020 Aug; 52(3):527-536. PubMed ID: 32598080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive Tests and Stool Frequency at Hospital Discharge Do Not Predict Outcomes in Hepatic Encephalopathy.
    Bloom PP; Miller SJ; Nayak RK; Hussain MS; Arvind A; Bay C; Chung RT
    South Med J; 2020 Nov; 113(11):578-584. PubMed ID: 33140112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlling nutritional status score as a new indicator of overt hepatic encephalopathy in cirrhotic patients following transjugular intrahepatic portosystemic shunt.
    Li J; Feng D; Pang N; Zhao C; Gao L; Liu S; Li L
    Clin Nutr; 2022 Feb; 41(2):560-566. PubMed ID: 35032860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement.
    Nardelli S; Lattanzi B; Torrisi S; Greco F; Farcomeni A; Gioia S; Merli M; Riggio O
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):934-936. PubMed ID: 27816756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis.
    Yip TC; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW; Wong GL
    Am J Gastroenterol; 2018 Nov; 113(11):1629-1638. PubMed ID: 30315283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary metabolic profiling by
    McPhail MJ; Montagnese S; Villanova M; El Hadi H; Amodio P; Crossey MM; Williams R; Cox IJ; Taylor-Robinson SD
    Metab Brain Dis; 2017 Apr; 32(2):331-341. PubMed ID: 27638475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis.
    Simón-Talero M; Roccarina D; Martínez J; Lampichler K; Baiges A; Low G; Llop E; Praktiknjo M; Maurer MH; Zipprich A; Triolo M; Vangrinsven G; Garcia-Martinez R; Dam A; Majumdar A; Picón C; Toth D; Darnell A; Abraldes JG; Lopez M; Kukuk G; Krag A; Bañares R; Laleman W; La Mura V; Ripoll C; Berzigotti A; Trebicka J; Calleja JL; Tandon P; Hernandez-Gea V; Reiberger T; Albillos A; Tsochatzis EA; Augustin S; Genescà J;
    Gastroenterology; 2018 May; 154(6):1694-1705.e4. PubMed ID: 29360462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hepatic transit times and liver elasticity compared with meld in predicting a 1 year adverse clinical outcome of a clinically diagnosed cirrhosis].
    Koller T; Piešťanská Z; Hlavatý T; Holomáň J; Glasa J; Payer J
    Vnitr Lek; 2016; 62(5):351-9. PubMed ID: 27319227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using machine learning methods to predict 28-day mortality in patients with hepatic encephalopathy.
    Zhang Z; Wang J; Han W; Zhao L
    BMC Gastroenterol; 2023 Apr; 23(1):111. PubMed ID: 37024814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.